High Risk Human Papilloma Virus (hrHPV) Screening for Anal Dysplasia and Anal Cancer

Overview

About this study

This study will aim to validate a new application of hrHPV testing for use in advancing science and improving patient care with regards to anal cancer screening.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients scheduled for surgery or a procedure involving anal biopsy for dysplasia or cancer OR
  • Patients undergoing anal biopsy due to positive anal cytology or other moderate risk factor for AIN3+

Exclusion Criteria: 

  • Those less than 35 years of age and who are not undergoing the above procedures noted in the inclusion criteria

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Binnicker, Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Kaitlin Schwartz

(507)293-9114

Schwartz.Kaitlin@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20416024

Mayo Clinic Footer